Unsecured Synthetic Royalties May Be Returning
The recent HCRx-Oncoceutics royalty monetization, following last year's Royalty Pharma-Revolution Medicines synthetic royalty financing, signals that investors are again willing to accept unsecured synthetic royalty exposure under the right circumstances....To view the full article, register now.
Already a subscriber? Click here to view full article